Sol-Gel Eyes 2028 Launch as SGT-610 Nears Pivotal Gorlin Syndrome Data

Impact · against what's priced in

Sol-Gel has established a concrete catalyst timeline with Phase III data for SGT-610 expected next month and a potential 2028 launch. While the $860 million peak US market opportunity is significant, the stock's near-term movement depends on the November data meeting the 40-50% treatment difference threshold.

SLGL+0.60

No priced-in read yet

In context

The company provides a specific catalyst window with topline Phase III data expected next month and a target 2028 US launch, targeting a $860 million market opportunity based on 4,000 treated patients.

Read from the article alone

• biotech
• healthcare
• pharmaceuticals
• SLGL
• clinical trials
• drug pipeline
• fda
• gorlin syndrome
• rare disease
• skin cancer

Search tags